<DOC>
	<DOCNO>NCT00138814</DOCNO>
	<brief_summary>This two arm randomize study patient undergo radiotherapy follow breast conservation surgery breast cancer . Local recurrence breast cancer compare patient receive boost boost radiotherapy .</brief_summary>
	<brief_title>Boost Use Breast Conservation Radiotherapy</brief_title>
	<detailed_description>A boost dose radiation commonly universally employ breast conservation technique . The potential disadvantage boost employ include : - Increased complexity treatment - Increased duration treatment - Increased travel , social/employment dislocation - Increased complication - Worse cosmesis and/or increase breast discomfort - Increased difficulty detect recurrence . - Prolongation gap increase delay chemotherapy indicate The potential advantage boost following : - Reduced local failure rate - Reduced local failure translate improve survival - Maximising cosmesis reduce dose large breast volume None potential advantage clearly demonstrate controlled fashion although sound theoretical reason boost improve local control . Holland 's landmark paper use radiologic-pathologic correlation mastectomy specimen , whilst find residual focus beyond boundary cosmetically acceptable resection margin , also find residual tumour relatively close index mass . There know dose-response control breast cancer . Kurtz report double longterm recurrence rate dose tumour bed le 75 Gy deliver less 8 Gy per week 15 % 30 % use telecesium follow lumpectomy . Treating entire breast dose 50 54 Gy 5 week associate significantly bad cosmesis , hence common use boost . There yet control comparison publish however Beadle report 50 % increase rate poor cosmesis boost employ . Borger demonstrate risk fibrosis increase fourfold every 100 cm3 increase boost volume . Accurate localisation tumour bed boost delivery difficult absence radioopaque clip ( uncommonly employ referral base ) . The use electron deliver boost report decrease cosmetic outcome compare I192 telangiectasia , although controversial report indicate superior result electron , modality available St George Wollongong . The latter avoids hospitalisation . There least one randomise multicentre study conduct test value boost EORTC Europe result yet available . Comparisons : Patients stratify chemotherapy ( none , AC , non-AC ) within non-AC arm randomise respect timing ( pre , sandwich , concurrent ) radiotherapy . Randomisation treatment - boost ( 45Gy 25 # + 16Gy 8 # ) boost ( 50Gy 25 # ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically proven carcinoma breast , T12 ( 05cm ) N01 , M0 . Pure ductal carcinoma situ accept completely excise . Any receptor status . Extensive intraductal cancer ( EIC ) accept completely excise . Unable consent Vascular/collagen disorder Prior malignancy except minor skin squamous cell basal cell carcinoma carcinoma insitu cervix . Gross multifocal disease Involvement margin . Bilateral breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Neoplasm recurrence , local</keyword>
	<keyword>Radiotherapy dosage</keyword>
	<keyword>Cosmesis</keyword>
	<keyword>Mastectomy , segmental</keyword>
</DOC>